NCT00404612

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 218 (actual)
• Sponsor: Lux Biosciences, Inc. · Industry
• Sex: All
• Age: 13 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis

Conditions

• Uveitis, Posterior
• Uveitis, Intermediate
• Panuveitis

Interventions

Type	Name	Description
DRUG	Placebo	PO BID
DRUG	LX211	0.2 mg/kg, twice a day (BID)
DRUG	LX211	0.4 mg/kg, twice a day (BID)
DRUG	LX211	0.6 mg/kg, twice a day (BID)

Timeline

• Start date: 2007-01-01
• Primary completion: 2008-11-01
• Completion: 2009-05-01
• First posted: 2006-11-29
• Last updated: 2012-10-11

Locations

41 sites across 7 countries: United States, Austria, Canada, France, Germany, India, United Kingdom